


AMENDMENT

U.S. Appln. No. 09/622,815


~~Please amend the claims as follows:~~

Claim 20. (Twice Amended) A compound which inhibits apoptosis or necrosis represented by formula (I):



(I)

wherein X represents an oxygen atom or N-R<sup>5</sup>; Z represents a halogen atom or



R<sup>1</sup> and R<sup>3</sup> each independently represents a hydrogen atom, an alkyl group which is substituted or unsubstituted, an alkenyl group which is substituted or unsubstituted, an alkynyl group which is substituted or unsubstituted, an aryl group which is substituted or unsubstituted, an acyl group which is substituted or unsubstituted, an alkoxy- or aryloxy carbonyl group which is substituted or unsubstituted, an alkyl- or arylthiocarbonyl group which is substituted or unsubstituted, an aminocarbonyl group which is substituted or unsubstituted, an alkyl- or arylsulfonyl group which is substituted or unsubstituted, an alkoxy group or an aryloxy group which is substituted or unsubstituted, or a hydroxyl group; R<sup>2</sup> and R<sup>4</sup> each represents substituent(s) on an indole ring, in which number and position

AMENDMENT

U.S. Appln. No. 09/622,815

(2-, 4-, 5-, 6-, or 7-position as position number of the indole ring) of the substituent(s) and kinds of the substituent(s) may be the same or different, and represents a hydrogen atom, an alkyl group which is substituted or unsubstituted, an alkenyl group which is substituted or unsubstituted, an alkynyl group which is substituted or unsubstituted, an aryl group which is substituted or unsubstituted, an acyl group which is substituted or unsubstituted, an alkoxy- or aryloxy carbonyl group which is substituted or unsubstituted, an alkyl- or arylthio carbonyl group which is substituted or unsubstituted, an aminocarbonyl group which is substituted or unsubstituted, an alkyl- or arylsulfonyl group which is substituted or unsubstituted, an alkoxy group or an aryloxy group which is substituted or unsubstituted, an alkyl- or arylthio group which is substituted or unsubstituted, a hydroxyl group, a carboxyl group, a cyano group, a nitro group, an amino group which is substituted or unsubstituted, or a halogen atom;  $R^5$  represents an alkyl group which is substituted or unsubstituted, an alkenyl group which is substituted or unsubstituted, an alkynyl group which is substituted or unsubstituted, an aryl group which is substituted or unsubstituted, an alkoxy group or an aryloxy group which is substituted or unsubstituted, an amino group which is substituted or unsubstituted, or a hydroxyl group;  $Y^1$  and  $Y^2$ , and  $Y^3$  and  $Y^4$  each independently represent two hydrogen atoms or a hydrogen atom and a hydroxyl group, or are combined to form a carbonyl group; and  $R^1$  and  $R^2$ ,  $R^1$  and  $R^3$ ,  $R^3$  and  $R^4$ , or  $R^2$  and  $R^4$  may be combined to form a hydrocarbon chain or a hydrocarbon chain containing hetero atom(s) which is substituted or


AMENDMENT

U.S. Appln. No. 09/622,815

unsubstituted; and in the formula, the bond accompanying a dotted line represents a double bond or a single bond, or a pharmaceutically acceptable salt thereof.

Claim 36. (Amended) The composition of Claim 21, wherein said composition is useful for treating functional deficiency of transplanted organs, tissues or cells.

Claim 39. (Amended) A composition comprising, as an active ingredient, a 2-halo-3-indolylmaleimide compound according to formula (II):



(II)

where Z<sup>1</sup> represents a halogen atom; R<sup>1</sup> represents a hydrogen atom, an alkyl group which is substituted or unsubstituted, an alkenyl group which is substituted or unsubstituted, an alkynyl group which is substituted or unsubstituted, an aryl group which is substituted or unsubstituted, acyl group which is substituted or unsubstituted, an alkoxy- or aryloxy carbonyl group which is substituted or unsubstituted, an alkyl- or arylthiocarbonyl group which is substituted or unsubstituted, an aminocarbonyl group which is substituted or unsubstituted, an alkyl- or arylsulfonyl group which is substituted or unsubstituted, an alkoxy group or an aryloxy group which is substituted or unsubstituted, or a hydroxyl group; R<sup>2</sup> represents substituent(s)

AMENDMENT

U.S. Appln. No. 09/622,815

on an indole ring, in which number and position (2-, 4-, 5-, 6-, or 7-position as position number of the indole ring) of the substituent(s) and kinds of the substituent(s) may be the same or different, and represents a hydrogen atom, an alkyl group which is substituted or unsubstituted, an alkenyl group which is substituted or unsubstituted, an alkynyl group which is substituted or unsubstituted, an aryl group which is substituted or unsubstituted, an acyl group which is substituted or unsubstituted, an alkoxy- or aryloxy carbonyl group which is substituted or unsubstituted, alkyl- or arylthiocarbonyl group which is substituted or unsubstituted, an aminocarbonyl group which is substituted or unsubstituted, an alkyl- or arylsulfonyl group which is substituted or unsubstituted, an alkoxyl group or an aryloxy group which is substituted or unsubstituted, an alkyl- or arylthio group which is substituted or unsubstituted, a hydroxyl group, a carboxyl group, a cyano group, a nitro group, an amino group which is substituted or unsubstituted, or a halogen atom;  $R^5$  represents an alkyl group which is substituted or unsubstituted, an alkenyl group which is substituted or unsubstituted, an alkynyl group which is substituted or unsubstituted, an aryl group which is substituted or unsubstituted, an alkoxyl group or an aryloxy group which is substituted or unsubstituted, an amino group which is substituted or unsubstituted, a hydroxyl group, or a hydrogen atom; and  $R^1$  and  $R^2$  may be combined to form a hydrocarbon chain or a hydrocarbon chain containing hetero atom(s) which is substituted or unsubstituted, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

AMENDMENT

U.S. Appln. No. 09/622,815

4  
Claim 42. (Amended) The method of Claim 41, wherein said subject has a disease selected from the group consisting of neurodegenerative disease, neonatal jaundice, myasthenia gravis, brain ischemia, delayed neuronal death, ischemic heart disease, viral myocarditis, autoimmune myocarditis, a myocardial disorder, hypertrophic heart, heart failure, arrhythmogenic right ventricular cardiomyopathy, alcoholic hepatitis, viral hepatitis, a renal disease, acquired immunodeficiency syndrome (AIDS), an inflammatory skin disorder, alopecia, graft versus host disease, a radiation disorder, a disorder due to a toxic agent, sepsis, osteomyelo-dysplasia, insulin dependent diabetes, and a prion disease.